

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/790,730	03/03/2004	Makoto Ozeki	1422-0625P	2621	
2292 BIRCH STFW	7590 09/18/200 /ART KOLASCH & BI	EXAM	EXAMINER		
PO BOX 747			CLAYTOR, DEIRDRE RENEE		
FALLS CHUR	RCH, VA 22040-0747		ART UNIT	PAPER NUMBER	
	•		1617		
			NOTIFICATION DATE	DELIVERY MODE	
			09/18/2007	ELECTRONIC	

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

		Application	ı No.	Applicant(s)	
Office Action Summary		10/790,730		OZEKI ET AL.	
		Examiner		Art Unit	
		Renee Clay	tor	1617	•
The MAIL Period for Reply	ING DATE of this communication a	appears on the	cover sheet with the c	orrespondence addr	ess
A SHORTENED WHICHEVER IS - Extensions of time ri after SIX (6) MONTH - If NO period for reply - Failure to reply withi Any reply received b	STATUTORY PERIOD FOR REF LONGER, FROM THE MAILING hay be available under the provisions of 37 CFR is from the mailing date of this communication. It is specified above, the maximum statutory perion to the set or extended period for reply will, by star by the Office later than three months after the main dijustment. See 37 CFR 1.704(b).	DATE OF THIS 2.1.136(a). In no even iod will apply and will atute, cause the applic	S COMMUNICATION t, however, may a reply be time expire SIX (6) MONTHS from ation to become ABANDONE	N. nely filed the mailing date of this comr D (35 U.S.C. § 133).	
Status	,	•			
2a) ☐ This action 3) ☐ Since this	e to communication(s) filed on <u>02</u> n is <b>FINAL</b> . 2b) The application is in condition for allow accordance with the practice unde	his action is no wance except for	or formal matters, pro		nerits is
Disposition of Clair	ns		•		
4a) Of the 5) ☐ Claim(s) _ 6) ☑ Claim(s) 4 7) ☐ Claim(s) _ 8) ☐ Claim(s) _  Application Papers 9) ☐ The specifi	cation is objected to by the Exami	d/or election red	quirement.		·
Applicant m Replaceme	g(s) filed on is/are: a) and a say not request that any objection to the antidrawing sheet(s) including the correct declaration is objected to by the	the drawing(s) be rection is required	held in abeyance. Seed if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR	• •
Priority under 35 U	S.C. § 119				
a) All b) Cert 2. Cert 3. Cop	gment is made of a claim for forei  Some * c) None of:  ified copies of the priority docume ified copies of the priority docume ies of the certified copies of the priority ication from the International Bure ched detailed Office action for a li	ents have been ents have been riority documen eau (PCT Rule	received. received in Applications have been received 17.2(a)).	on No ed in this National St	age
	son's Patent Drawing Review (PTO-948) ure Statement(s) (PTO/SB/08)		1) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	ate	

Art Unit: 1617

#### **DETAILED ACTION**

Applicant's remarks filed on 7/2/2007 have been fully considered. Applicant's admission that the Japanese 2003-63958 document is not a patent but is an application is persuasive. Therefore, the 35 USC 102(d) rejection is hereby withdrawn.

Applicant's remarks over the Obviousness-type Double Patenting rejections have been considered. Upon further consideration it is noted that the claims of Application 10/311,972 are now relating to tension during physical exercise, which the Examiner does not consider obvious over the present invention. Therefore, the rejection is being withdrawn.

Applicant's remarks over the Obviousness-type Double Patenting rejection over Application 10/343,931 have been considered and are not found persuasive. Applicants argue that ADHD is a distinct disorder than mood disorders. This is not persuasive because as the claim reads, a mood disorder can be anything that that affects the mood and ADHD is a disorder that is known to affect the mood of an individual. Therefore, the rejection is maintained.

The following new grounds of rejection are given below.

### Claim Rejections – 35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the

Art Unit: 1617

applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 4 and 6 rejected under 35 U.S.C. 102(e) as being anticipated by Ueda et al. (U.S. Patent 6,831,103).

Ueda et al. teaches the administration of a theanine-containing composition that is capable of ameliorating symptoms such as mental symptoms (i.e., depressive state or spiritlessness) associated with premenstrual syndrome (PMS; Col. 5, lines 10-38). Column 5 lists more symptoms that are associated with mood that meet the broad limitation of "mood disorder" listed in claim 4. Ueda et al. further teach that theanine may be contained in different types of food or beverages (Col. 6, lines 8-67 – Col. 7, lines 1-17).

### Claim Rejections - 35 U.S.C. § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 5 and 7-12 rejected under 35 U.S.C. 103(a) as being unpatentable over Ueda et al. (U.S. Patent 6,831,103) as applied to claims 4 and 6 above in view of Hamilton (J Neurol Neurosurg Psychiat, 1960, 23, 56).

Application/Control Number: 10/790,730 Page 4

Art Unit: 1617

Ueda et al. teach a method for ameliorating different types of mood, such as a depressed mental state and spiritlessness (meeting the limitations of claims 5, 8 and 12, with a food or beverage containing theanine.

Ueda et al. do not specifically teach that the mood is assessed by the Hamilton scale or all of the different types of mood listed in claims 9-11.

Hamilton teaches a rating scale for measuring symptoms of mental disorder, including the symptoms such as depressed mood, feelings of guilt, suicide, retardation:psychomotor and diminished insight (see whole document).

Accordingly, it would be obvious to a person of ordinary skill in the art at the time of the invention that the Hamilton scale would be an effective assessment of symptoms of mood disorders because of the teachings of Ueda et al. that theanine containing compositions are effective in treating various types of mood, particularly those associated with premenstrual syndrome. It would further be obvious that theanine would treat depressed state or other forms of mood regardless of how the state manifested, i.e. a person that is not suffering from premenstrual syndrome. One would be motivated to use the Hamilton scale because it is a scale commonly used to assess various mood disorders, including depressed states. Therefore, the other factors in the scale would also be measured.

#### Conclusion

No claims are allowed.

Application/Control Number: 10/790,730

Art Unit: 1617

### **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is 571-272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

SPEENI PADMANADITATI SUPERVISORY PATENT EXAMINER

Page 5